Board of Directors

Charles W. Newhall, III has served as a member of the Board since 2005. In 1977, Mr. Newhall co-founded New Enterprise Associates, Inc. (NEA), a venture capital firm that focuses on the medical and life sciences and information technology industries. Mr.

Dr. Carrolee Barlow, M.D., Ph.D., was appointed to the Board of Directors in June 2018. Dr. Barlow is a renowned expert in neuroscience, neurodegeneration and rare diseases, and is currently the Chief Medical Officer of ESCAPE Bio. Dr. Barlow’s previous work spanned clinical care, laboratory and

Georges Gemayel, PhD, was appointed as a director of the Company effective March 23, 2015. Dr. Gemayel has more than 25 years of experience in the pharmaceutical industry, including management and executive positions spanning the United States, Europe and the Middle East and mostly at Roche, at

Frederick M. Hudson has served as a member of the Board since 2010. Mr. Hudson retired as a partner in charge of the healthcare audit practice for the Washington-Baltimore business unit of the accounting firm of KPMG, LLP, on January 1, 2006, after a 37-year career with the firm.

Jack A. Khattar is the founder of Supernus Pharmaceuticals and has served as President and Chief Executive Officer and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions, including Board Member, President, and CEO of Shire Laboratories Inc., the drug delivery subsidiary

John M. Siebert, PhD has served as a member of the Board since 2011. Dr. Siebert has more than 30 years of experience in the pharmaceutical industry. Since 2009, he has been Chairman and CEO of Compan Pharmaceuticals, LLC, a veterinary specialty company.

Bethany Sensenig was appointed to the Board of Directors in August 2023. Ms. Sensenig has more than 20 years of business and strategic financial leadership experience in the pharmaceutical and biotechnology sectors. Ms. Sensenig was the Chief Financial Officer and Interim Chief Executive Officer of